Skip to main content
. 2024 May 3;26(Suppl 2):S155–S164. doi: 10.1093/neuonc/noae001

Table 1.

Demographic and Baseline Characteristics

Parameter Patients (n = 12)
Age, median (range), years 9 (4–18)
Female sex, n (%) 8 (66.7)
Race, n (%)
 White 9 (75.0)
 Unknown 2 (16.7)
 Other 1 (8.3)
Body weight, median (range), kg 34.7 (15.3–63.7)
KPS/LPS, median (range)
 <80 3 (25.0)
 ≥80 9 (75.0)
Time from diagnosis, median (range), month 5.9 (3.0–13.1)
Primary tumor location, n (%)
 Pons 8 (66.7)
 Thalamus 2 (16.7)
 Midbrain 1 (8.3)
 Spinal cord 1 (8.3)
Diagnosis, n (%)
 Diffuse midline glioma, H3 K27M-mutant 8 (66.7)
  DIPG (biopsied) 4 (33.3)
  Non-DIPG (biopsied) 4 (33.3)
 DIPG (nonbiopsied) 4 (33.3)
Multifocal disease, n (%)
 Yes 2 (16.7)
 No 10 (83.3)
Disease status, n (%)
 Post radiation, not recurrent 8 (66.7)
 Recurrent 4 (33.3)
H3 K27M mutation method, n (%)
 Immunohistochemistry 5 (41.7)
 Next-generation sequencing 3 (25.0)
  H3.3 K27M mutation 3 (25.0)
  H3.1 K27M mutation 0
 Unknown 4 (33.3)
Number of recurrences, n (%)
 0 8 (66.7)
 1 2 (16.7)
 ≥2 2 (16.7)
Time from prior radiation, median (range), days 60.5 (29.0–290)
Re-irradiation, n (%) 3 (25.0)
Dexamethasone daily dose, median (range), mg 0.2 (0–4)